Presta LG - Search Results

1

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Clynes RA, Towers TL, Presta LG, Ravetch JV. Clynes RA, et al. Among authors: presta lg. Nat Med. 2000 Apr;6(4):443-6. doi: 10.1038/74704. Nat Med. 2000. PMID: 10742152

2

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P. Shalaby MR, et al. J Exp Med. 1992 Jan 1;175(1):217-25. doi: 10.1084/jem.175.1.217. J Exp Med. 1992. PMID: 1346155 Free PMC article.

3

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. Shields RL, et al. Among authors: presta lg. J Biol Chem. 2001 Mar 2;276(9):6591-604. doi: 10.1074/jbc.M009483200. Epub 2000 Nov 28. J Biol Chem. 2001. PMID: 11096108 Free article.

4

An efficient route to human bispecific IgG.

Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. Merchant AM, et al. Among authors: presta lg. Nat Biotechnol. 1998 Jul;16(7):677-81. doi: 10.1038/nbt0798-677. Nat Biotechnol. 1998. PMID: 9661204

5

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.

Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, Meng YG, Mulkerrin MG. Idusogie EE, et al. Among authors: presta lg. J Immunol. 2000 Apr 15;164(8):4178-84. doi: 10.4049/jimmunol.164.8.4178. J Immunol. 2000. PMID: 10754313 Free article.

6

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Shields RL, et al. Among authors: presta lg. J Biol Chem. 2002 Jul 26;277(30):26733-40. doi: 10.1074/jbc.M202069200. Epub 2002 May 1. J Biol Chem. 2002. PMID: 11986321 Free article.

7

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Adams CW, et al. Cancer Immunol Immunother. 2006 Jun;55(6):717-27. doi: 10.1007/s00262-005-0058-x. Epub 2005 Sep 3. Cancer Immunol Immunother. 2006. PMID: 16151804

8

Design, construction, and in vitro analyses of multivalent antibodies.

Miller K, Meng G, Liu J, Hurst A, Hsei V, Wong WL, Ekert R, Lawrence D, Sherwood S, DeForge L, Gaudreault J, Keller G, Sliwkowski M, Ashkenazi A, Presta L. Miller K, et al. J Immunol. 2003 May 1;170(9):4854-61. doi: 10.4049/jimmunol.170.9.4854. J Immunol. 2003. PMID: 12728922 Free article.

9

Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation.

Eigenbrot C, Meng YG, Krishnamurthy R, Lipari MT, Presta L, Devaux B, Wong T, Moran P, Bullens S, Kirchhofer D. Eigenbrot C, et al. J Mol Biol. 2003 Aug 8;331(2):433-46. doi: 10.1016/s0022-2836(03)00735-6. J Mol Biol. 2003. PMID: 12888350

10

Protein structure analysis and development of databases.

Presta L. Presta L. Protein Eng. 1989 Mar;2(6):395-7. doi: 10.1093/protein/2.6.395. Protein Eng. 1989. PMID: 2710778 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results